Research progress of PD-1/PD-L1 inhibitors in the treatment of peripheral T-cell lymphomas

LUO Qian; ZOU Liqun

doi:10.19401/j.cnki.1007-3639.2020.12.012

您当前的位置：

首页 >

文章列表页 >

Research progress of PD-1/PD-L1 inhibitors in the treatment of peripheral T-cell lymphomas

更新时间：2026-01-27

- Research progress of PD-1/PD-L1 inhibitors in the treatment of peripheral T-cell lymphomas
- China Oncology Vol. 30, Issue 12, Pages: 1035-1040(2020)
- 作者机构：
  
  1. 四川大学华西临床医学院,四川,成都,610041
  2. 四川大学华西医院肿瘤一科,四川,成都,610041
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2020.12.012
  CLC：
- Published Online：08 January 2021，
  
  Published：08 January 2021
- 稿件说明：
移动端阅览
骆　倩 , 邹立群 . PD-1/PD-L1抑制剂在外周T细胞淋巴瘤治疗中的研究进展#br#[J]. 中国癌症杂志, 2020, 30(12): 1035-1040.

LUO Qian, ZOU Liqun. Research progress of PD-1/PD-L1 inhibitors in the treatment of peripheral T-cell lymphomas[J]. China Oncology, 2020, 30(12): 1035-1040.
骆　倩 , 邹立群 . PD-1/PD-L1抑制剂在外周T细胞淋巴瘤治疗中的研究进展#br#[J]. 中国癌症杂志, 2020, 30(12): 1035-1040. DOI： 10.19401/j.cnki.1007-3639.2020.12.012.

LUO Qian, ZOU Liqun. Research progress of PD-1/PD-L1 inhibitors in the treatment of peripheral T-cell lymphomas[J]. China Oncology, 2020, 30(12): 1035-1040. DOI： 10.19401/j.cnki.1007-3639.2020.12.012.

摘要

外周T细胞淋巴瘤（peripheral T-cell lymphoma

PTCL）是一组高度异质性和侵袭性的非霍奇金淋巴瘤（non-Hodgkin’s lymphoma，NHL）。在目前化疗为主的治疗下，PTCL患者通常预后差，复发率高，因此需要积极探索新药来改善预后。肿瘤微环境（tumor microenvironment，TME）在多种肿瘤中发挥重要作用，程序性死亡［蛋白］-1（programmed death-1，PD-1）/程序性死亡［蛋白］配体-1（programmed death ligand-1，PD-L1）信号通路是参与肿瘤免疫逃逸的重要途径之一，针对PD-1/PD-L1通路的抑制剂在多种肿瘤中疗效显著，在PTCL的治疗上也有广阔的应用前景。研究表明在PTCL多种亚型中均有不同程度PD-1/PD-L1的表达，且PD-1单抗在部分亚型中疗效显著。现就PD-1/PD-L1在PTCL中的表达情况和其抑制剂的治疗进展作一综述。

Abstract

Peripheral T-cell lymphomas (PTCLs) are a group of highly heterogeneous and aggressive non-Hodgkin’s lymphoma (NHL). PTCL patients have poor prognosis and high rates of relapse under the current chemotherapy-based treatment. Therefore

new drugs should be developed to improve the prognosis of PTCL. Tumor microenvironment (TME) plays an important role in many tumors. Programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) signaling pathway is one of the most important pathways involved in tumor immune escape. Inhibitors of the PD-1/PD-L1 pathway have exhibited remarkable effects in the treatment of multiple tumors and have broad application prospects in PTCL. Studies have found varying degrees of expressions of PD-1 and its ligands in multiple PTCL subtypes

and the PD-1 inhibitor has significant efficacy in some subtypes. In this paper

we reviewed the expression of PD-1/PD-L1 in PTCL and the therapeutic role of its inhibitors.

关键词

Keywords

references

Views

7346

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

AI问答

⁰